NasdaqGS:INCYBiotechs
Incyte (INCY) Valuation Check As New Povorcitinib Phase 3 Data Draws Investor Interest
Incyte (INCY) is back in focus after releasing 54 week Phase 3 data for its JAK1 inhibitor povorcitinib in moderate to severe hidradenitis suppurativa, alongside ongoing regulatory reviews in the US and Europe.
See our latest analysis for Incyte.
Alongside the new povorcitinib data and fresh collaboration and leadership updates, Incyte’s 7 day share price return of 5.01% contrasts with a 90 day share price return decline of 11.06%, while the 1 year total shareholder return of 57.34% points to...